Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01361945 | AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Texas Tech University Health Sciences Center, El PasoOTHER | 0 | May 9, 2017 | clinicaltrials |
| NCT01227408 | Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT00397501 | BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain | withdrawn | Phase 1 / Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | withdrawn | Phase 2 | 0 | Peregrine PharmaceuticalsINDUSTRY | 0 | Mar 9, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT00450515 | Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Dec 6, 2016 | clinicaltrials |
| NCT01479179 | Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2016 | clinicaltrials |
| NCT02610621 | Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy | withdrawn | Phase 2 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT02725541 | Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer(NATURE) | withdrawn | Phase 2 | 0 | Jenny C. Chang, MDOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT02539017 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT02338531 | Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer(RHEA) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 2 | Apr 29, 2016 | clinicaltrials |
| NCT02215876 | Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01410708 | TORI 104 Pre-Surgical Dasatinib | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01985893 | Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer(THOR) | withdrawn | Phase 2 | 0 | Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT02140437 | Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 0 | Dec 29, 2015 | clinicaltrials |
| NCT00343759 | Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy | withdrawn | Phase 2 | 0 | University of PennsylvaniaOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT00075413 | Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | The University of Texas Medical Branch, GalvestonOTHER | 0 | Oct 2, 2015 | clinicaltrials |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Sep 17, 2015 | clinicaltrials |
| NCT02053597 | TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen(TRIUMPH) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02396433 | Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers | withdrawn | Phase 1 / Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Aug 25, 2015 | clinicaltrials |
| NCT00022230 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roger Williams Medical CenterOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00471159 | A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer. | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | May 4, 2015 | clinicaltrials |
| NCT00678626 | Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | May 4, 2015 | clinicaltrials |
| NCT01757327 | LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Apr 27, 2015 | clinicaltrials |
| NCT01008514 | Partial-Breast Radiation Therapy in Treating Women With Early-Stage Breast Cancer | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Mar 26, 2015 | clinicaltrials |
| NCT00575978 | Hydralazine as Demethylating Agent in Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 0 | Mar 4, 2015 | clinicaltrials |
| NCT01479946 | Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin | withdrawn | Phase 2 | 0 | Uppsala University HospitalOTHER | 1 | Dec 9, 2014 | clinicaltrials |
| NCT01953445 | Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Dec 8, 2014 | clinicaltrials |
| NCT02115594 | Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer(ENCORE305) | withdrawn | Phase 2 | 0 | Syndax PharmaceuticalsINDUSTRY | 1 | Oct 8, 2014 | clinicaltrials |
| NCT01913067 | Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC(CRANIAL) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Jul 24, 2014 | clinicaltrials |
| NCT01814865 | Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer | withdrawn | Phase 2 | 0 | British Columbia Cancer AgencyOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT01240941 | Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 20, 2013 | clinicaltrials |
| NCT00003455 | Antineoplaston Therapy in Treating Women With Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003536 | Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00080613 | Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer | withdrawn | Phase 2 | — | Robert H. Lurie Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01614184 | Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT01557764 | Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 4, 2013 | clinicaltrials |
| NCT01013506 | Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | May 23, 2013 | clinicaltrials |
| NCT01137994 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Mar 13, 2013 | clinicaltrials |
| NCT01612728 | Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer(AIA) | withdrawn | Phase 2 | 0 | Baylor Breast Care CenterOTHER | 0 | Feb 12, 2013 | clinicaltrials |
| NCT00227474 | S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Jan 24, 2013 | clinicaltrials |
| NCT00217659 | S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 3, 2013 | clinicaltrials |
| NCT01658176 | Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Oct 29, 2012 | clinicaltrials |
| NCT01163929 | A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer | withdrawn | Phase 2 | 0 | University of KansasOTHER | 0 | Oct 24, 2012 | clinicaltrials |
| NCT00005614 | Management of Metastatic Breast Cancer in Frail Patients | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 25, 2012 | clinicaltrials |
| NCT00434031 | CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer(CETRA) | withdrawn | Phase 2 | 0 | National Cancer Institute, NaplesOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT01005641 | ELBA: Exemestane and Lapatinib in Advanced Breast Cancer(ELBA) | withdrawn | Phase 2 | 0 | National Cancer Institute, NaplesOTHER | 1 | Jul 13, 2012 | clinicaltrials |
Data updated 23 days agoSource updated May 9, 2017source: clinicaltrials